Update on immunogenicity in severe asthma: Experience with mepolizumab.

Autor: Ortega HG; Respiratory US Medical Affairs, GSK, La Jolla, Calif. Electronic address: hortega@gossamerbio.com., Meyer E; GSK, Philadelphia, Pa., Brusselle G; Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium., Asano K; Pulmonary Medicine, Tokai University School of Medicine, Kanagawa, Japan., Prazma CM; Respiratory Medical Franchise, GSK, Research Triangle Park, NC., Albers FC; Respiratory Medical Franchise, GSK, Research Triangle Park, NC., Mallett SA; Clinical Statistics, GSK, Stockley Park, Uxbridge, Middlesex, United Kingdom., Yancey SW; Respiratory Medical Franchise, GSK, Research Triangle Park, NC., Gleich GJ; School of Medicine, University of Utah, Utah.
Jazyk: angličtina
Zdroj: The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2019 Sep - Oct; Vol. 7 (7), pp. 2469-2475.e1. Date of Electronic Publication: 2019 Apr 05.
DOI: 10.1016/j.jaip.2019.03.042
Databáze: MEDLINE